Michelle Rissling1Lianqi Liu2Shawn D. Youngstedt3Vera Trofimenko4Loki Natarajan5,6Ariel B. Neikrug7Neelum Jeste8Barbara A. Parker2,6Sonia Ancoli-Israel1,6* 1Department of Psychiatry, University of California, San Diego, San Diego, CA, United States 2Department of Medicine, University of California, San Diego, San Diego, CA, United States 3Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, United States 4St. Joseph Hospital, Orange, CA, United States 5Family Medicine and Public Health, University of California, San Diego, San Diego, CA, United States 6Moores Cancer Center, University of California, San Diego, San Diego, CA, United States 7Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA, United States 8Johnson & Johnson, San Diego, CA, United States

In the published article, there was an error in Table 2 as published. The sample size numbers were reversed. The Bright White Light Group sample size numbers in the original table were really the sample sizes for the Dim Red Light group, and visa versa. The correct sample size numbers appear in the corrected table. The corrected Table 2 and its caption appear below.

Table 2. Mean (SE) PSQI total and component scores by group condition and mixed model analysis.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: breast cancer, light therapy, sleep, actigraphy, PSQI, activity

Citation: Rissling M, Liu L, Youngstedt SD, Trofimenko V, Natarajan L, Neikrug AB, Jeste N, Parker BA and Ancoli-Israel S (2024) Corrigendum: Preventing sleep disruption with bright light therapy during chemotherapy for breast cancer: a phase II randomized controlled trial. Front. Neurosci. 18:1386314. doi: 10.3389/fnins.2024.1386314

Received: 15 February 2024; Accepted: 01 July 2024;
Published: 03 October 2024.

Edited and reviewed by: Joy Perrier, Neuropsychologie et Imagerie de la Mémoire Humaine, France

Copyright © 2024 Rissling, Liu, Youngstedt, Trofimenko, Natarajan, Neikrug, Jeste, Parker and Ancoli-Israel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Sonia Ancoli-Israel, sancoliisrael@health.ucsd.edu